Amneal Pharmaceuticals (AMRX) Interest & Investment Income (2017 - 2026)

Amneal Pharmaceuticals has reported Interest & Investment Income for 10 years, with the latest figure at -$55.0 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 15.45% year-over-year to -$55.0 million in Q2 2026; TTM through Jun 2026 was -$227.5 million, a 8.73% increase from a year earlier, with the FY2025 full-year figure at -$241.1 million, up 6.77% from the prior year.
• Interest & Investment Income was -$55.0 million for Q2 2026 at Amneal Pharmaceuticals, down from -$53.4 million in the prior quarter.
• The five-year high for Interest & Investment Income was -$33.3 million in Q1 2022, with the low at -$65.7 million in Q2 2024.
• Average Interest & Investment Income over 5 years is -$54.3 million, with a median of -$55.6 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2026: Interest & Investment Income sank 47.94% in 2023, then advanced 15.45% in 2026.
• Over 5 years, Interest & Investment Income stood at -$47.0 million in 2022, then fell by 26.62% to -$59.5 million in 2023, then decreased by 3.55% to -$61.7 million in 2024, then climbed by 8.8% to -$56.2 million in 2025, then advanced by 2.12% to -$55.0 million in 2026.
• The last three Interest & Investment Income figures came in at -$55.0 million (Q2 2026), -$53.4 million (Q1 2026), and -$56.2 million (Q4 2025), per Business Quant data.